氯氮平治疗难治性精神分裂症的反应率：系统评价和荟萃分析的数据。
Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis.
机构信息
1 Metro South Addiction and Mental Health Services, Brisbane, Australia.
2 University of Queensland School of Medicine, Brisbane, Australia.
出版信息
Can J Psychiatry. 2017 Nov;62(11):772-777. doi: 10.1177/0706743717718167. Epub 2017 Jun 28.
Abstract
Clozapine is the most effective antipsychotic for the 25% to 33% of people with schizophrenia who are treatment resistant, but not all people achieve response. Using data from a previously published clozapine systematic review and meta-analysis, we explored the proportion of people who achieved response and examined the absolute and percentage change in Positive and Negative Syndrome Scale (PANSS) scores. Overall, 40.1% (95% confidence interval [CI], 36.8%-43.4%) responded, with a mean reduction in PANSS of 22.0 points (95% CI, 20.9-23.1), a reduction of 25.8% (95% CI, 24.7%-26.9%) from baseline. These reductions are clinically meaningful. A 40% response rate to clozapine suggests that 12% to 20% of people with schizophrenia will be ultra-resistant.
摘要
氯氮平是治疗抵抗的 25%至 33%精神分裂症患者最有效的抗精神病药物，但并非所有人都能达到疗效。利用先前发表的氯氮平系统评价和荟萃分析的数据，我们探讨了达到疗效的人群比例，并检查阳性和阴性症状量表（PANSS）评分的绝对和百分比变化。总体而言，40.1%（95%置信区间[CI]，36.8%-43.4%）的患者有反应，PANSS 平均降低 22.0 分（95%CI，20.9-23.1），与基线相比降低了 25.8%（95%CI，24.7%-26.9%）。这些减少具有临床意义。氯氮平的 40%反应率表明，12%至 20%的精神分裂症患者将具有超强耐药性。
相似文献
1
Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis.氯氮平治疗难治性精神分裂症的反应率：系统评价和荟萃分析的数据。
Can J Psychiatry. 2017 Nov;62(11):772-777. doi: 10.1177/0706743717718167. Epub 2017 Jun 28.
2
Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia.氯氮平联合不同抗精神病药物治疗难治性精神分裂症。
Cochrane Database Syst Rev. 2017 Mar 23;3(3):CD006324. doi: 10.1002/14651858.CD006324.pub3.
3
Antipsychotic combinations for schizophrenia.用于精神分裂症的抗精神病药物联合治疗
Cochrane Database Syst Rev. 2017 Jun 28;6(6):CD009005. doi: 10.1002/14651858.CD009005.pub2.
4
Clozapine versus typical neuroleptic medication for schizophrenia.氯氮平与传统抗精神病药物治疗精神分裂症的比较。
Cochrane Database Syst Rev. 2009 Jan 21;2009(1):CD000059. doi: 10.1002/14651858.CD000059.pub2.
5
The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis.拉莫三嗪治疗氯氮平难治性精神分裂症的疗效：一项系统评价和荟萃分析。
Schizophr Res. 2009 Apr;109(1-3):10-4. doi: 10.1016/j.schres.2009.01.002. Epub 2009 Jan 30.
6
Clozapine versus typical neuroleptic medication for schizophrenia.氯氮平与传统抗精神病药物治疗精神分裂症的比较。
Cochrane Database Syst Rev. 2000(2):CD000059. doi: 10.1002/14651858.CD000059.
7
Clozapine dose for schizophrenia.用于治疗精神分裂症的氯氮平剂量。
Cochrane Database Syst Rev. 2017 Jun 14;6(6):CD009555. doi: 10.1002/14651858.CD009555.pub2.
8
Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms.抗精神病药治疗伴有紧张症症状的精神分裂症谱系障碍。
Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD013100. doi: 10.1002/14651858.CD013100.pub2.
9
Sertindole for schizophrenia.用于治疗精神分裂症的舍吲哚。
Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2.
10
Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia.氯氮平联合不同抗精神病药物治疗难治性精神分裂症。
Cochrane Database Syst Rev. 2009 Jul 8(3):CD006324. doi: 10.1002/14651858.CD006324.pub2.
引用本文的文献
1
Cariprazine and clozapine: a systematic review of a promising antipsychotic combination for treatment-resistant schizophrenia.卡立哌嗪与氯氮平：对一种有前景的用于治疗难治性精神分裂症的抗精神病药物组合的系统评价
Int J Neuropsychopharmacol. 2025 Aug 1;28(8). doi: 10.1093/ijnp/pyaf053.
2
Efficacy and tolerability of pharmacological interventions for schizophrenia non-responsive to prior treatment: a systematic review and network meta-analysis.对先前治疗无反应的精神分裂症药物干预的疗效和耐受性：一项系统评价和网状Meta分析
EClinicalMedicine. 2025 Jun 7;84:103291. doi: 10.1016/j.eclinm.2025.103291. eCollection 2025 Jun.
3
Reduced SARS-CoV-2 vaccine-specific antibody response associated with high clozapine doses in schizophrenia spectrum disorders.在精神分裂症谱系障碍中，高剂量氯氮平与严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗特异性抗体反应降低有关。
Brain Behav Immun Health. 2025 May 19;46:101016. doi: 10.1016/j.bbih.2025.101016. eCollection 2025 Jul.
4
Putative Mechanisms of Electroconvulsive Therapy in Treatment-Resistant Schizophrenia Examined Using Magnetic Resonance Imaging.使用磁共振成像研究电休克治疗难治性精神分裂症的潜在机制。
Biol Psychiatry Glob Open Sci. 2025 Apr 1;5(4):100494. doi: 10.1016/j.bpsgos.2025.100494. eCollection 2025 Jul.
5
Effectiveness of clozapine augmentation with specific doses of other antipsychotics in schizophrenia: a meta-analysis from two nationwide cohorts.特定剂量的其他抗精神病药物与氯氮平联合治疗精神分裂症的有效性：来自两个全国性队列的荟萃分析
World Psychiatry. 2025 Jun;24(2):250-259. doi: 10.1002/wps.21316.
6
Exploring the role of autistic traits in treatment-resistant and clozapine-resistant schizophrenia: a comparative study.探索孤独症特质在难治性和氯氮平抵抗性精神分裂症中的作用：一项比较研究。
Front Psychiatry. 2025 Apr 29;16:1541469. doi: 10.3389/fpsyt.2025.1541469. eCollection 2025.
7
Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part I: A Review of the Pharmacokinetic Literature and Proposed Changes.致美国食品药品监督管理局的信：提议对美国氯氮平药品说明书进行重大修改，全球氯氮平专家提供支持。第一部分：药代动力学文献综述及提议的修改内容。
J Clin Psychopharmacol. 2025;45(3):179-196. doi: 10.1097/JCP.0000000000001987. Epub 2025 Apr 9.
8
Two Long-Acting Antipsychotics in a Patient with Treatment-Resistant Schizophrenia: A Case Report.难治性精神分裂症患者使用两种长效抗精神病药物：一例病例报告
Clin Pract. 2025 Mar 10;15(3):55. doi: 10.3390/clinpract15030055.
9
Predictors of clozapine concentration and psychiatric symptoms in patients with schizophrenia.精神分裂症患者中氯氮平浓度及精神症状的预测因素
PLoS One. 2025 Mar 6;20(3):e0319037. doi: 10.1371/journal.pone.0319037. eCollection 2025.
10
Theoretical Potential of Hericium Erinaceus Supplementation as an Add-On to Antipsychotics in Chronic and Treatment-Resistant Schizophrenia.猴头菇辅助抗精神病药物治疗慢性难治性精神分裂症的理论潜力
Psychopharmacol Bull. 2025 Feb 3;55(2):41-59.
本文引用的文献
1
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology.难治性精神分裂症：精神病治疗反应与抵抗（TRRIP）工作组关于诊断和术语的共识指南
Am J Psychiatry. 2017 Mar 1;174(3):216-229. doi: 10.1176/appi.ajp.2016.16050503. Epub 2016 Dec 6.
2
Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis.氯氮平与第一代和第二代抗精神病药治疗难治性精神分裂症的比较：系统评价和荟萃分析。
Br J Psychiatry. 2016 Nov;209(5):385-392. doi: 10.1192/bjp.bp.115.177261. Epub 2016 Jul 7.
3
Clozapine Underutilization in the Treatment of Schizophrenia: How Can Clozapine Prescription Rates Be Improved?氯氮平在精神分裂症治疗中的使用不足：如何提高氯氮平的处方率？
J Clin Psychopharmacol. 2016 Apr;36(2):109-11. doi: 10.1097/JCP.0000000000000478.
4
Increasing Clozapine Dispensing Trends in Queensland, Australia 2004-2013.2004 - 2013年澳大利亚昆士兰州氯氮平配药趋势增加
Pharmacopsychiatry. 2015 Jul;48(4-5):164-9. doi: 10.1055/s-0035-1554713. Epub 2015 Jun 19.
5
Equipercentile linking of the BPRS and the PANSS.BPRS 和 PANSS 的等百分位链接。
Eur Neuropsychopharmacol. 2013 Aug;23(8):956-9. doi: 10.1016/j.euroneuro.2012.11.004. Epub 2013 Feb 22.
6
Psychiatry, the pharmaceutical industry, and the road to better therapeutics.精神病学、制药行业与通往更好治疗方法之路。
Schizophr Bull. 2012 Jun;38(4):649-50. doi: 10.1093/schbul/sbs073.
7
Minimum clinically important difference in the Positive and Negative Syndrome Scale with data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE).阳性与阴性症状量表的最小临床重要差异：来自干预有效性的临床抗精神病药物试验（CATIE）的数据。
J Clin Psychiatry. 2012 Apr;73(4):526-32. doi: 10.4088/JCP.11m07162.
8
An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis.基于算法的首发精神分裂症治疗方法：3 项前瞻性抗精神病药物试验和回顾性数据分析的应答率。
J Clin Psychiatry. 2011 Nov;72(11):1439-44. doi: 10.4088/JCP.09m05785yel. Epub 2011 Mar 8.
9
Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study.齐拉西酮与氯氮平治疗对多种抗精神病药物治疗无效的精神分裂症患者：莫扎特研究
Schizophr Res. 2009 May;110(1-3):80-9. doi: 10.1016/j.schres.2009.02.017. Epub 2009 Mar 9.
10
A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia.氯氮平与高剂量奥氮平治疗难治性精神分裂症患者的随机双盲对照研究。
J Clin Psychiatry. 2008 Feb;69(2):274-85. doi: 10.4088/jcp.v69n0214.
Zotero 插件